Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II study of hu14.18-IL2 [EMD 273063] in children with recurrent or refractory neuroblastoma

Trial Profile

A phase II study of hu14.18-IL2 [EMD 273063] in children with recurrent or refractory neuroblastoma

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Feb 2015

At a glance

  • Drugs Monoclonal antibody ch14 18 interleukin-2 fusion protein (Primary)
  • Indications Neuroblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 02 Feb 2011 This study data provided drug development checkpoints to proceed to phase III in certain pediatric neuroblastoma subjects and Apeiron plans to continue clinical development in 2011, according to an Apeiron Biologics media release.
    • 26 Mar 2008 Status changed from in progress to completed according to clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top